DRI Capital is a private investment firm that seeks to acquire royalties from pharmaceutical and biotechnology companies, research institutions, universities, and inventors. DRI Capital’s focus is on products that treat chronic, critical and/or rare diseases and which improve the health and quality of a patient’s life. In addition to the traditional focus on pharmaceutical products, DRI Capital considers investments in royalty entitlements on medical devices, diagnostic products and life science tools and technologies. DRI Capital was established in 1992 and is headquartered in Toronto, Ontario.
Join Mergr to view the latest updates and news from DRI Capital.
Join Mergr to view DRI Capital’s full profile and discover more large private equity firms just like it.
No obligation. Cancel anytime.